Close Menu

NEW YORK (GenomeWeb) – Agilent Technologies announced today that it has signed a co-development agreement with China-based molecular diagnostics developer Burning Rock under which Burning Rock will create cancer diagnostics for the Chinese market based on the Agilent SureSelect target enrichment system.

Burning Rock said it will register any molecular diagnostic kit it develops through this deal with the China Food and Drug Administration, adding that such a kit could become the first CFDA-approved capture sequencing-based cancer diagnostic assay in China.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.